Embecta Corp (EMBC)vsMedline Inc. Class A Common Stock (MDLN)
EMBC
Embecta Corp
$3.49
+6.08%
HEALTHCARE · Cap: $184.51M
MDLN
Medline Inc. Class A Common Stock
$33.61
-2.44%
HEALTHCARE · Cap: $65.23B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 2695% more annual revenue ($29.14B vs $1.04B). EMBC leads profitability with a 10.7% profit margin vs 3.3%. EMBC trades at a lower P/E of 1.6x. EMBC earns a higher WallStSmart Score of 53/100 (C-).
EMBC
Buy53
out of 100
Grade: C-
MDLN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.4%
Fair Value
$7.32
Current Price
$3.49
$3.83 premium
Intrinsic value data unavailable for MDLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Earnings expanding 1258.0% YoY
Large-cap with strong market position
Reasonable price relative to book value
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 14.4%
Premium valuation, high expectations priced in
Distress zone — elevated risk
3.3% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Market Cap, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
EMBC profiles as a declining stock while MDLN is a value play — different risk/reward profiles.
MDLN is growing revenue faster at 10.7% — sustainability is the question.
MDLN generates stronger free cash flow (316M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EMBC scores higher overall (53/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a prominent medical technology company dedicated to innovating insulin delivery systems for diabetes management. Established as a spin-off from Becton, Dickinson and Company, Embecta offers a wide range of advanced products, including state-of-the-art insulin pens and syringes, designed to improve patient outcomes. With a strong commitment to operational excellence and customer satisfaction, Embecta is strategically poised to leverage growth opportunities in the expanding diabetes care market, thereby reinforcing its leadership role in this critical sector.
Visit Website →Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?